Dec 11, 2025 1:00pm EST MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
Dec 11, 2025 9:00am EST MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
Dec 11, 2025 8:00am EST MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential
Dec 10, 2025 2:00pm EST MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
Nov 21, 2025 9:01am EST MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
Nov 20, 2025 8:47am EST MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation
Oct 27, 2025 10:45am EDT MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 23, 2025 8:36am EDT MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
